Hypermethylation of the CDKN2/p16INK4A promotor in thyroid carcinogenesis.

Functional inactivation of the p16INK4A gene has been reported to be involved in the development of a variety of human malignancies. In thyroid carcinomas, mutations of the p16INK4A gene or homozygous deletions of the gene locus 9p21 are rare. This study investigated whether p16INK4A promotor methylation is an alternative mechanism for p16INK4A gene inactivation during thyroid carcinogenesis. A methylation-specific polymerase chain reaction protocol was applied. A total of 77 thyroid tumor specimens, including 18 follicular adenomas, 18 follicular carcinomas, 16 papillary carcinomas, 12 poorly differentiated carcinomas, and 13 undifferentiated carcinomas were analyzed longitudinally. In addition, 15 tumor-free thyroid tissues were investigated. The p16INK4A promotor status was compared with p16INK4A protein expression and patient-specific data. p16INK4A promotor hypermethylation was detected in 13% of non-tumorous tissue; in 33% of follicular adenomas; in 44% of papillary carcinomas; in 50% of follicular carcinomas; in 75% of poorly differentiated carcinomas; and in 85% of undifferentiated carcinomas. With the exception of two cases, the p16INK4A protein was lost as a result of promotor hypermethylation. Comparing the methylation status with tumor stage, no correlation was found. However, lymph node and distant metastasis status showed a statistically significant prevalence for the p16INK4A promotor methylation (p = 0.035). There was no association between p16INK4A promotor methylation and age and sex. These results suggest that hypermethylation of the p16INK4A promotor region is a frequent and an early event during thyroid carcinogenesis and is associated with tumor progression and dedifferentiation.

[1]  R. Schneider-Stock,et al.  High prognostic value of p16INK4 alterations in gastrointestinal stromal tumors. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Miano,et al.  The highly malignant phenotype of anaplastic thyroid carcinoma cell lines is recessive. , 2000, European journal of endocrinology.

[3]  J. Zedenius,et al.  Molecular Genetics of Thyroid Tumors and Surgical Decision-making , 2000, World Journal of Surgery.

[4]  J. Bullerdiek,et al.  Structural abnormalities of chromosome 2 in benign thyroid tumors. Three new cases and review of the literature. , 1999, Cancer genetics and cytogenetics.

[5]  J. Fagin,et al.  Genetic and epigenetic alterations of the cyclin‐dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas , 1998, Cancer.

[6]  C. Hsieh,et al.  Hypermethylation of the p16INK4a promoter in colectomy specimens of patients with long-standing and extensive ulcerative colitis. , 1998, Cancer research.

[7]  D. Wong,et al.  p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas. , 1997, Cancer research.

[8]  C. Sherr.  Cancer Cell Cycles , 1996, Science.

[9]  Carissa A. Sanchez,et al.  Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus. , 1996, Oncogene.

[10]  A. Fusco,et al.  Status and expression of the p16INK4 gene in human thyroid tumors and thyroid‐tumor cell lines , 1996, International journal of cancer.

[11]  J. Herman,et al.  Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. , 1995, Cancer research.

[12]  R. Beart,et al.  Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. , 1995, Cancer research.

[13]  Kathleen R. Cho,et al.  Frequency of homozygous deletion at p16/CDKN2 in primary human tumours , 1995, Nature Genetics.

[14]  J. Herman,et al.  5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers , 1995, Nature Medicine.

[15]  M. Skolnick,et al.  A cell cycle regulator potentially involved in genesis of many tumor types. , 1994, Science.

[16]  G. Hannon,et al.  A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.

[17]  M. Pierotti,et al.  Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. , 1993, The Journal of clinical investigation.

[18]  M. Pierotti,et al.  TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes in human papillary thyroid carcinomas. , 1992, Oncogene.

[19]  R. Kerr.  Reading the Future in Loma Prieta: October's earthquake was disastrous enough, but its successful forecast and the lessons of history suggest worse is in store, perhaps within the next decade. , 1989, Science.